(177)Lu-Prostate-Specific Membrane Antigen Ligand After (223)Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience

We analyzed real-world clinical outcomes of sequential α-/β-emitter therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We assessed safety and overall survival in 26 patients who received (177)Lu-prostate-specific membrane antigen ligand ((177)Lu-PSMA) after (223)Ra in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartor, Oliver, la Fougère, Christian, Essler, Markus, Ezziddin, Samer, Kramer, Gero, Ellinger, Jörg, Nordquist, Luke, Sylvester, John, Paganelli, Giovanni, Peer, Avivit, Bögemann, Martin, Meltzer, Jeffrey, Sandström, Per, Verholen, Frank, Song, Daniel Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978191/
https://www.ncbi.nlm.nih.gov/pubmed/34168015
http://dx.doi.org/10.2967/jnumed.121.262240

Ejemplares similares

Ejemplares similares